Business Context and Reporting Period
Company: Aastrom Biosciences, Inc. (Note: The input metadata referenced "Vericel Corp," but the filing text explicitly identifies the registrant as Aastrom Biosciences, Inc.)
Reporting Period: Quarterly Report on Form 10-Q for the period ended December 31, 2006.
Business Stage: Clinical development stage company focused on autologous cell products (Tissue Repair Cells or TRCs) for regenerative medicine (bone, vascular, cardiac, and neural tissues). The company has not yet achieved profitability and relies on equity financing and grants.
Key Financial Metrics
| Metric | Three Months Ended Dec 31, 2006 | Six Months Ended Dec 31, 2006 | Balance Sheet (Dec 31, 2006) |
|---|---|---|---|
| Total Revenues | $158,000 | $262,000 | - |
| Net Loss | $(4,225,000) | $(8,282,000) | - |
| Net Loss Per Share | $(0.04) | $(0.07) | - |
| Cash & Cash Equivalents | - | - | $13,979,000 |
| Short-Term Investments | - | - | $22,333,000 |
| Total Liquid Assets | - | - | $36,312,000 |
| Accumulated Deficit | - | - | $(150,432,000) |
| Current Liabilities | - | - | $2,317,000 |
Note: All figures in thousands except per share data.
Material Changes vs. Prior Period
- Revenue: Total revenue increased to $158,000 for the quarter (from $117,000 in the prior year quarter), driven primarily by an increase in grant revenue ($152,000 vs. $75,000). Product sales declined significantly to $6,000 (from $42,000).
- Expenses: Total costs and expenses rose to $4.90 million for the quarter (from $4.46 million).
- R&D Expenses: Increased to $2.56 million (from $2.20 million) due to expanded clinical trials and regulatory activities.
- SG&A Expenses: Increased to $2.33 million (from $2.26 million), largely due to a one-time non-cash stock-based compensation charge of $257,000 related to the former CEO's option amendment.
- Liquidity: Combined cash and short-term investments decreased by approximately $6.7 million from June 30, 2006, to December 31, 2006, reflecting operating cash burn.
Outlook, Risks, and Management Commentary
- Clinical Progress:
- Bone Regeneration: Phase I/II trial for long bone fractures completed enrollment; interim results showed bone bridging in 10 of 12 patients with 12-month follow-up. A pivotal trial for osteonecrosis of the femoral head initiated in Spain in January 2007.
- Vascular Regeneration: Pilot trial for critical limb ischemia in Germany is ongoing.
- Cardiac: Received FDA Orphan Drug Designation for dilated cardiomyopathy in February 2007.
- Liquidity Outlook: Management believes current cash, investments, and interest income are sufficient to fund operations beyond June 30, 2008. Monthly cash utilization is estimated at approximately $1.5 million.
- Capital Needs: The company expects to require additional funding to complete clinical trials and commercialize products. Future funding may come from equity sales, debt, or collaborations.
- Risks:
- Significant operating losses and no history of profitability.
- Dependence on regulatory approvals (FDA/EMA) which are uncertain and costly.
- Reliance on third-party manufacturers for clinical trial supplies.
- Potential delisting from Nasdaq if stock price remains below $1.00.
- Management turnover (new CEO appointed July 2006; former CEO left board Nov 2006).
Investor Verification Checklist
- Cash Runway: Verify if the $36.3 million in liquid assets is sufficient to cover the projected $1.5 million monthly burn rate through 2008 without dilution.
- Clinical Trial Data: Confirm the final results of the long bone fracture trial (expected late 2007) and the safety data from the vascular trial in Germany.
- Regulatory Status: Monitor the progress of the Biologic License Application (BLA) preparation and the impact of EU regulatory changes on clinical trial timelines.
- Stock-Based Compensation: Review the valuation of the performance-based stock options granted to key employees, as the fair value is still being estimated and could impact future expenses.
- Revenue Mix: Assess the sustainability of grant revenue, which comprised 93% of total revenue for the six-month period, versus the negligible product sales.